STOCK TITAN

Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Pelthos Therapeutics (PTHS) reported third-quarter Zelsuvmi net product revenue of $15.2 million, more than doubling from the year-earlier quarter.

Revenue rose 114% year over year but fell 1% sequentially. Units dispensed reached 12,384, up 4% sequentially and 365% year over year. Net loss narrowed to $7.9 million from $16.2 million a year earlier and $23.4 million in the second quarter. Cash was $17.7 million at September 30.

Pelthos borrowed another $10.0 million in October, bringing Horizon borrowings to $40.0 million. Its Castle Creek merger is expected to close by the end of the first quarter of 2027, subject to Castle Creek stockholder approval and other closing conditions. The deal would add the late-stage D-Fi gene-modified cell therapy for dystrophic epidermolysis bullosa, a skin disease. Pelthos targets Xepi and Xeglyze launches in the first and third quarters of 2027, respectively.

Loading...
Loading translation...
15 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 13 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Castle Creek's definitive merger agreement would add late-stage D-Fi and a cell and gene therapy platform.
  • Major pointOctober Horizon borrowing added $10.0 million in funding. 27% of market cap
  • Moderate pointZelsuvmi revenue reached $15.2 million, up 114% year over year but down 1% sequentially.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Pelthos targets Xepi in first-quarter 2027 and Xeglyze in third-quarter 2027 for launch.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Pelthos expects cash, October borrowing and commercial projections to support its current business plan.
  • Moderate pointQuarterly net loss narrowed to $7.9 million from $16.2 million year earlier and $23.4 million sequentially.
9 minor points
  • Minor pointZelsuvmi dispensing reached 12,384 units, up 4% sequentially and 365% year over year.
  • Minor pointZelsuvmi commercial formulary coverage reached 127 million lives, or 69%; Medicaid coverage exceeded 70 million, or 100%.
  • Minor pointQuarterly loss per share narrowed to $2.04 from $5.30 year earlier and $6.62 sequentially.
  • Minor pointQuarterly operating loss narrowed to $9.693 million from $15.362 million year earlier and $17.323 million sequentially.
  • Minor pointCost of goods sold fell to $1.7 million, down 28% year over year and 54% sequentially.
  • Minor pointSG&A expenses were $18.8 million, down 25% sequentially but up 3% year over year.
  • Minor pointConvertible-debt valuation produced a $4.1 million gain, versus a $3.7 million second-quarter loss.
  • Minor pointAdjusted EBITDA loss narrowed to $5.6 million from $10.4 million year earlier and $5.7 million sequentially.
  • Minor pointNine-month net product revenue reached $41.298 million, versus $7.112 million a year earlier.

Negative

  • Major pointHorizon senior secured borrowings reached $40.0 million following the October draw. 1.1× market cap
  • Moderate pointNine-month net loss widened to $56.385 million from $21.655 million a year earlier.
  • Moderate pointStockholders' equity shifted to a $6.186 million deficit from $38.881 million at December 31, 2025.
  • Moderate pointTotal liabilities increased to $135.003 million from $91.516 million at December 31, 2025.
  • Minor pointCastle Creek merger completion remains subject to Castle Creek stockholder approval and other closing conditions.
8 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional Horizon funding of $10.0 million primarily requires trailing twelve-month net revenue of at least $70.0 million.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pelthos expects a slight increase in gross-to-net deductions as new coverage is implemented.
  • Minor pointQuarterly research and development expense rose to $1.019 million from $145,000 year earlier and $600,000 sequentially.
  • Minor pointQuarterly royalty expense reached $2.510 million, versus $1.245 million year earlier and $2.639 million sequentially.
  • Minor pointQuarterly interest expense was $2.269 million, versus $1.346 million year earlier and $2.389 million sequentially.
  • Minor pointQuarterly license and collaboration revenue declined to $182,000 from $294,000 year earlier and $183,000 sequentially.
  • Minor pointNine-month operating loss widened to $40.104 million from $20.427 million a year earlier.
  • Minor pointCash declined to $17.690 million at September 30, 2026, from $17.973 million at December 31, 2025.

News Explained

The additional ten million dollars is conditional borrowing capacity, not committed funding.

The amended agreement provides a senior secured term-loan facility of up to $50.0 million; a further $10.0 million may be available before December 31, 2027, primarily if trailing-12-month net revenue reaches at least $70.0 million.

As of September 30, 2026, Pelthos reported approximately 9.1 million shares outstanding on an as-converted basis, including preferred-stock conversions, versus approximately 3.9 million common shares issued and outstanding.

Argus Nov 12 session 10 alerts
-14.48% close to close 2.0x rel. volume Open Argus
Details

News Market Reaction – PTHS

-11.7% Trough in 49 min
$34.68M Mkt Cap at Peak Alert

On Nov 12, the day this news came out, PTHS closed 14.48% below the previous close. Argus tracked a trough of -11.7% from its starting point during tracking. Our momentum scanner recorded 10 alerts for this stock that day. That session’s volume was 2.0x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Nov 12 session.

Key Figures

Zelsuvmi net product revenue: $15.2 million; +114% year over year; -1% quarter over quarter Zelsuvmi units dispensed: 12,384 units; +365% year over year; +4% quarter over quarter Commercial formulary coverage: 127 million covered lives; 69% of commercially covered lives +4 more
Zelsuvmi net product revenue
$15.2 million; +114% year over year; -1% quarter over quarter
Third quarter 2026
Zelsuvmi units dispensed
12,384 units; +365% year over year; +4% quarter over quarter
Third quarter 2026
Commercial formulary coverage
127 million covered lives; 69% of commercially covered lives
Zelsuvmi coverage reported during third quarter 2026
Cash and additional borrowing
$17.7 million cash at September 30; additional $10.0 million borrowed October 30
Cash balance excludes the subsequent borrowing
Horizon term loan facility
Up to $50.0 million; $40.0 million outstanding
After the October 30, 2026 amendment and additional draw
Net loss
$(7.9) million
Third quarter 2026, compared with $(16.2) million in Q3 2025 and $(23.4) million in Q2 2026
Adjusted EBITDA
$(5.6) million
Third quarter 2026, compared with $(10.4) million in Q3 2025 and $(5.7) million in Q2 2026

Previous Earnings Reports

3 past events · Latest: Aug 13
Same Type 3 events
  1. Aug 13

    Earnings report

    24h Move
    +0.1%

    Q2 Zelsuvmi revenue reached $15.4 million, with units dispensed up 48% quarter over quarter.

  2. May 14

    Earnings report

    24h Move
    +6.5%

    Q1 Zelsuvmi revenue rose to $10.7 million, with units dispensed up 25% quarter over quarter.

  3. Mar 19

    Earnings report

    24h Move
    -4.6%

    Q4 Zelsuvmi net product revenue was $9.1 million, with 8,948 units dispensed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

orphan drug designation, fast track, regenerative medicine advanced therapy, convertible notes, +1 more
5 terms
orphan drug designation regulatory
"received Orphan Drug designation for DEB and Rare Pediatric Disease"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
fast track regulatory
"Fast Track and Regenerative Medicine Advanced Therapy designations"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
regenerative medicine advanced therapy regulatory
"Regenerative Medicine Advanced Therapy designations from the FDA"
Regenerative Medicine Advanced Therapy (RMAT) is a U.S. regulatory designation for cell, gene, and tissue‑based therapies intended to treat serious or life‑threatening conditions; it gives developers a “fast lane” with more frequent agency interaction and eligibility for accelerated review pathways. For investors, an RMAT label signals that a therapy may reach market faster and face less regulatory uncertainty than a standard program, which can raise the potential value and reduce timeline risk—though it is not a guarantee of approval.
convertible notes financial
"the Company’s existing convertible notes and its Horizon facility"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
gross-to-net deductions financial
"increased formulary position, and optimized gross-to-net deductions"
Amounts subtracted from a seller’s reported gross sales to arrive at net sales or net revenue; in pharmaceutical and healthcare contexts this typically includes rebates, chargebacks, discounts, returns, patient assistance/copay support, government program rebates and other allowances that reduce the amount the manufacturer actually expects to collect. Companies record gross-to-net deductions when they recognize revenue, often as estimated reserves that are adjusted later when actual claims, rebates or returns are settled. The exact categories and accounting treatment vary by industry and contract, so the total and timing of these deductions are company‑specific and may be revised after initial reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025

12,384 Zelsuvmi units were dispensed by 4,942 unique prescribers during the third quarter of 2026, representing a 4% quarter-over-quarter increase in units dispensed

Increased formulary coverage for Zelsuvmi® to 127 million commercially covered lives

Recently announced transaction with Castle Creek, creating transformative biotechnology company focused on serious diseases that affect the skin

Management will host a conference call today, November 12, 2026, at 8:30 a.m. ET


DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos,” “we” or the “Company”), today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million,” said Scott Plesha, CEO of Pelthos. “Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”

“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company,” Mr. Plesha continued. “This transformative merger brings together two complementary platforms across different therapeutic modalities and has significant upside potential through Castle Creek’s fibroblast-based cell and gene therapy technology, and its lead candidate, D-Fi, which has the potential to become a blockbuster franchise in dystrophic epidermolysis bullosa, or DEB. We look forward to completing the transaction and delivering significant value to our shareholders.”

Third Quarter and Recent Business Highlights

Zelsuvmi® Commercial Highlights

  • Zelsuvmi® net product revenue was $15.2 million in the third quarter of 2026, up 114% from $7.1 million in the third quarter of 2025, driven by strong utilization of Zelsuvmi by health care providers, increased formulary position, and optimized gross-to-net deductions.

  • In the third quarter, units of Zelsuvmi dispensed increased to 12,384 units, up 4% from the prior quarter and up 365% from the same period last year.

  • Third-quarter net revenue per unit reflected increased utilization of Zelsuvmi associated with expanding access, consistent with expectations for this stage of launch. As new coverage is implemented, Pelthos expects a slight increase in gross-to-net deductions, and improving net revenue per unit over time.

  • During the third quarter of 2026, Pelthos announced that it had secured new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives, gained enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives, and increased formulary coverage for Zelsuvmi to 127 million commercially covered lives or 69% of commercially covered lives and strong Medicaid coverage of more than 70 million or 100% of covered lives.

Combination with Castle Creek Presents Compelling Value Opportunity

On October 30, 2026, the Company announced that it entered into a definitive merger agreement under which Castle Creek Biosciences, Inc. (“Castle Creek”), a late-stage company developing redosable gene therapies, will merge into an affiliate of Pelthos via a series of mergers. The combination would create a transformative, diversified biotechnology company with a synergistic pediatric and dermatological focus, targeting serious diseases that affect the skin. Castle Creek’s late-stage fibroblast-based cell and gene therapy platform, including its lead candidate, D-Fi, complements the Company’s three novel FDA-approved products and established commercial capabilities in dermatology, with the potential to drive long-term value for shareholders. D-Fi is a redosable, gene-modified cell therapy for DEB that has received Orphan Drug designation for DEB and Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy designations from the FDA for recessive DEB.

  • The transaction remains on track to close by the end of the first quarter of 2027, subject to customary closing conditions including approval by Castle Creek’s stockholders.

  • The combined company is expected to offer compelling complementary capabilities, greater pipeline diversification and an expanded technology base.

  • As part of the Pelthos’ portfolio, D-Fi will leverage the Company’s established commercial leadership, and deep expertise in dermatology. The merger offers important synergy in prescribers and key opinion leaders as both D-Fi and Pelthos’ current portfolio are focused on providing important therapies to the pediatric dermatology, dermatology and pediatric specialties.

  • Bringing together Pelthos’ three novel FDA-approved products, Zelsuvmi®, Xepi® and Xeglyze®, with D-Fi will create a portfolio spanning marketed, launch-stage and late-stage assets that provides multiple potential sources of growth over different time horizons.

  • In addition, Castle Creek’s fibroblast technology adds a cell and gene therapy capability to Pelthos’ existing Nitricil technical and manufacturing platform, giving the combined company multiple therapeutic modalities to address serious skin diseases where conventional small molecules have had limited impact and allowing it to expand its product pipeline over time.

Other Financial Highlights

  • Pelthos’ cash balance as of September 30, 2026 was $17.7 million, not including an additional $10.0 million borrowed from Horizon Technology Finance on October 30, 2026. This additional borrowing, paired with cash on hand, combined with the Company’s current commercial projections, is expected to support its current business plan.

  • On October 30, 2026, Pelthos entered into an Amended and Restated Venture Loan and Security Agreement with Horizon Technology Finance, which amended and restated the Company’s original Venture Loan and Security Agreement (January 2026). The amended agreements provides for a senior secured term loan facility of up to $50.0 million. In connection with the amendment, the Company drew an additional $10.0 million, bringing current outstanding borrowings to $40.0 million. An additional $10.0 million may be available in funding prior to December 31, 2027, primarily subject to the Company achieving trailing twelve-month net revenue of at least $70.0 million.

  • As of September 30, 2026, we had approximately 9.1 million shares outstanding on an as-converted basis, which includes the conversion of approximately 51,479 shares of the Company’s Series A and 2,600 shares of Series C Convertible Preferred Stock, and approximately 3.9 million shares of common stock issued and outstanding.

Third Quarter 2026 Financial Summary

  • Net product revenues for Zelsuvmi during the third quarter of 2026 was $15.2 million as compared to $7.1 million during the third quarter of 2025 and $15.4 million during the second quarter of 2026, representing a 114% year-over-year increase and a 1% quarter-over-quarter decrease, respectively.
  • Cost of goods sold was $1.7 million for the third quarter of 2026 as compared to $2.3 million for the third quarter of 2025 and $3.6 million for the second quarter of 2026, representing a 28% year-over-year reduction and a 54% quarter-over-quarter reduction, respectively. Cost of goods sold includes fair value adjustments related to finished goods and active pharmaceutical ingredient inventory on hand at the time of the Company’s merger in July 2025. Cost of goods sold for the second quarter of 2026 also included a $0.9 million write-off of work-in-process inventory related to specification tolerances.
  • Selling, general and administrative (“SG&A”) expenses were $18.8 million for the third quarter of 2026 as compared to $18.4 million for the third quarter of 2025 and $25.0 million for the second quarter of 2026, representing a 3% year-over-year increase and a 25% quarter-over quarter reduction. SGA expenses for the second quarter of 2026 included $5.3 million of one-time milestone expense.
  • Interest expense was $2.3 million for the third quarter of 2026 compared to $1.3 million for the third quarter of 2025 and $2.4 million for the second quarter of 2026. Interest expense is attributable to (i) the Company’s existing convertible notes and its Horizon facility; and (ii) the accounting treatment of certain royalty and purchase agreement obligations entered into by the Company.
  • Change in fair value of debt, related to the convertible notes issued in November 2025, was a $4.1 million gain in the third quarter of 2026 compared to a $3.7 million loss for the second quarter of 2026. There was no corresponding change in fair value of debt in the third quarter of 2025 because the convertible notes had not yet been issued. At issuance, the Company analyzed the terms of the convertible notes and its embedded features concluding it was appropriate to account for the convertible notes at fair value. Accordingly, the Company initially recognized the convertible notes at fair value and will subsequently measure the convertible notes at fair value with changes in fair value recorded in current period earnings or other comprehensive income.
  • Net loss for the third quarter of 2026 was $(7.9) million, compared to $(16.2) million for the third quarter of 2025 and $(23.4) million for the second quarter of 2026.
  • Adjusted EBITDA for the third quarter of 2026 was $(5.6) million, as compared to $(10.4) million for the third quarter of 2025 and $(5.7) million for the second quarter of 2026, as discussed within the Non-GAAP Financial Information below.
  • See additional detail within the Summary Financial Statement tables and Non-GAAP Financial Information below.

Webcast and Conference Call

Management will host a conference call and webcast today at 8:30 a.m. ET to discuss the Company’s third quarter 2026 results and provide a corporate update. Interested parties may participate in the call by dialing:

(877) 451-6152 (Domestic)
(201) 389-0879 (International)
Conference ID: 13763737

The live webcast will be accessible in the Investors section of the Company’s website or by following the direct link:

https://viavid.webcasts.com/starthere.jsp?ei=1782128&tp_key=f03f47add7

For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Pelthos’ website.

About Pelthos Therapeutics

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. Zelsuvmi® (berdazimer) topical gel, 10.3%, the Company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) the potential benefits of the merger with Castle Creek, including potential synergies and capabilities of the combined company, and the anticipated timing of closing; (ii) the anticipated ongoing growth for Zelsuvmi®; (iii) the potential timing for the commercialization and anticipated launch of Xepi and Xeglyze; (iv) our belief that the exclusion of certain items in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our business; and (vi) our belief that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company’s Common Stock will be indicative of the combined company’s value or that the combined company’s Common Stock will become an attractive investment in the future; the closing conditions required under the Castle Creek merger agreement, which may not be satisfied or completed on a timely basis, if at all; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
Jude Gorman / Dylan O’Keefe
Collected Strategies
Pelthos-CS@collectedstrategies.com

Summary Financial Statements

Pelthos Therapeutics Inc.
Selected Condensed Consolidated Balance Sheet Data
(unaudited)
(in thousands)
 September 30,
2026
 December 31,
2025
Cash and cash equivalents$ 17,690   $ 17,973
Accounts receivable, net  13,413     8,858
Inventory  21,471     23,574
Total current assets  56,066     53,410
Total assets  128,817     130,397
    
Accounts payable$ 3,717   $ 2,986
Accrued expenses  23,155     15,364
Total current liabilities  31,435     25,993
Total liabilities  135,003     91,516
    
Total stockholders' (deficit) equity$ (6,186) $ 38,881
Total liabilities and stockholders' equity  128,817     130,397



Pelthos Therapeutics Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands except share and per share data)
    
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2026   2025   2026   2025 
        
Revenue       
Net product revenues$ 15,213  $ 7,112  $ 41,298  $ 7,112 
License and collaboration revenues  182    294    606    294 
Total revenue  15,395    7,406    41,904    7,406 
Operating expenses       
Cost of goods sold  1,661    2,316    6,944    2,316 
Selling, general and administrative  18,845    18,383    63,117    22,739 
Research and development  1,019    145    1,805    854 
Royalty expense  2,510    1,245    7,015    1,245 
Amortization of intangible assets  1,05     679    3,127    679 
Total operating expenses  25,088    22,768    82,008    27,833 
Operating loss  (9,693)   (15,362)   (40,104)   (20,427)
Other (expense) income       
Interest expense  (2,269)   (1,346)   (7,011)   (1,698)
Change in fair value of convertible debt  4,067    —    (9,270)   — 
Interest income and other income  —    5    —     5 
Total other (expense) income  1,798    (1,341)   (16,281)   (1,693)
Net loss before provision (benefit) for income taxes  (7,895)   (16,703)   (56,385)   (22,120)
Provision (benefit) for income taxes  —    (465)   —     (465)
Net loss$ (7,895) $ (16,238) $ (56,385) $ (21,655)
        
Net loss per common share - basic and diluted$ (2.04) $ (5.30) $ (15.78) $ (14.92)
        
Weighted average number of common shares outstanding - basic and diluted 3,862,896   3,061,735   3,573,387   1,451,152 


Pelthos Therapeutics Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands except share and per share data)
    
 Three Months Ended
 September 30, 2026 June 30, 2026
    
Revenue   
Net product revenues$ 15,213  $ 15,420 
License and collaboration revenues  182    183 
Total revenue  15,395    15,603 
Operating expenses   
Cost of goods sold  1,661    3,610 
Selling, general and administrative  18,845    25,034 
Research and development  1,019    600 
Royalty expense  2,510    2,639 
Amortization of intangible assets  1,053    1,043 
Total operating expenses  25,088    32,926 
Operating loss  (9,693)   (17,323)
Other (expense) income   
Interest expense  (2,269)   (2,389)
Change in fair value of convertible debt  4,067    (3,705)
Total other (expense) income  1,798    (6,094)
Net loss before provision for income taxes  (7,895)   (23,417)
Provision for income taxes  —     —  
Net loss$ (7,895) $ (23,417)
    
Net loss per common share - basic and diluted$ (2.04) $ (6.62)
Weighted average number of common shares
outstanding - basic and diluted
 3,862,896   3,539,464 


Non-GAAP Financial Information

Adjusted EBITDA

To provide investors with additional information regarding the Company’s financial results, we have provided within this press release Adjusted EBITDA, a non-GAAP financial measure. We define Adjusted EBITDA as net loss adjusted to eliminate (i) stock-based compensation expense, (ii) the inventory valuation step-up recognized in cost of goods sold resulting from the July 1, 2025 acquisition of LNHC, Inc., as described below, (iii) change in fair value of convertible debt, (iv) milestones due to license agreement counterparties, (v) interest expense, (vi) interest and other income, (vii) amortization of intangible assets, (viii) depreciation expense, and (ix) the provision for income taxes. We have provided a reconciliation below of Net Loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA.

The Company accounts for business acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, Fair Value Measurements (“ASC 820”), as of the acquisition date. As part of the July 1, 2025 acquisition of LNHC, Inc., the fair value of the inventory acquired was estimated using the top/down method that considers the estimated selling price, costs to complete, disposal costs, profit margin on disposal effort, and holding costs. Significant assumptions include management’s estimates for the selling price and the costs to be incurred related to the disposal effort of the inventory. The non-cash inventory valuation step-up from the acquisition of LNHC, Inc. is recognized within cost of goods sold in the periods presented.

We have included Adjusted EBITDA in this press release because it is a key measure used by our management to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget and to develop short- and long-term operating plans. In particular, we believe the exclusion of certain items from net loss in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP.

The following table presents a reconciliation of Net Loss to Adjusted EBITDA for each of the periods indicated (in thousands):

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2026   2025   2026   2025 
Net loss $ (7,895) $ (16,238) $ (56,385) $ (21,655)
Adjustments:       
Stock-based compensation  1,943    2,812    6,611    3,662 
Cost of goods sold basis step-up  823    1,111    4,757    1,111 
Change in fair value of convertible debt  (4,067)   —    9,270    — 
Milestone expense  —    —    5,250    — 
Interest expense  2,269    1,346    7,011    1,698 
Interest income and other income  —    (5)   —    (5)
Amortization of intangible assets  1,053    679    3,127    679 
Depreciation  283    389    1,030    389 
Provision (benefit) for income taxes  —    (465)   —    (465)
Adjusted EBITDA$ (5,591) $ (10,371) $ (19,329) $ (14,586)


 Three Months Ended
 September 30, 2026 June 30, 2026
Net loss $ (7,895) $ (23,417)
Adjustments:   
Stock-based compensation  1,943    2,760 
Cost of goods sold basis step-up  823    2,295 
Change in fair value of convertible debt  (4,067)   3,705 
Milestone expense  —    5,250 
Interest expense  2,269    2,389 
Amortization of intangible assets  1,053    1,043 
Depreciation  283    278 
Adjusted EBITDA$ (5,591) $ (5,697)



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Pelthos Therapeutics' third-quarter 2026 financial results?

Pelthos reported $15.2 million in Zelsuvmi net product revenue and a $7.9 million net loss. Product revenue increased 114% year over year but decreased 1% sequentially. Net loss narrowed from $16.2 million a year earlier and $23.4 million in the second quarter.

When is the Pelthos and Castle Creek merger expected to close?

The merger is expected to close by the end of the first quarter of 2027, subject to Castle Creek stockholder approval and other closing conditions. Castle Creek would merge into an affiliate of Pelthos through a series of mergers.

What conditions apply to Pelthos' remaining Horizon loan funding?

An additional $10.0 million may be available before December 31, 2027, primarily subject to Pelthos achieving trailing twelve-month net revenue of at least $70.0 million. The amended senior secured term loan facility provides for up to $50.0 million.

What affected Pelthos' second-quarter expense comparisons?

Second-quarter 2026 expenses included a $0.9 million inventory write-off in cost of goods sold and a $5.3 million one-time milestone expense in selling, general and administrative expenses. The inventory write-off concerned work-in-process inventory related to specification tolerances.

Keep reading